Paper Details

  1. Home
  2. Paper Details

Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).

Author: AbgrallJ F, AudhuyB, BriereJ, CahnJ Y, CaillotD, CasassusP, DelainM, DesablensB, FrancoisS, GuilhotF, GuyotatD, HarousseauJ L, HerveP, HurteloupP, LamyT, LioureB, MilpiedN, PignonB, TellierZ, WitzF

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

In a study of 517 people with acute myeloid leukemia (AML) under 40 who achieved remission, three intensive treatment options were compared: allogeneic bone marrow transplant (alloBMT), autologous bone marrow transplant (ASCT), and intensive chemotherapy (ICC). While alloBMT was associated with better outcomes for those with a suitable donor, there was no significant difference in survival between ASCT and ICC. The study found that a second round of chemotherapy after a first round of ICC was less toxic than ASCT, with similar survival rates. Overall, the type of treatment after remission did not significantly affect outcomes, suggesting that the initial white blood cell count and type of leukemia are more important factors in survival.
Paper Details　
Original Abstract of the Article :
Three intensive consolidation strategies are currently proposed to younger adults with acute myeloid leukemia (AML) in first complete remission (CR): allogeneic or autologous bone marrow transplantation (BMT) and intensive consolidation chemotherapy (ICC). Patients aged 15 to 50 years with de novo A...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/9376578

データ提供：米国国立医学図書館（NLM）

Post-Remission Therapy for AML: Exploring the Landscape of Options

Acute myeloid leukemia (AML), a type of blood cancer, presents a challenging journey for patients. This study investigates the effectiveness of different post-remission therapies, comparing autologous bone marrow transplantation (BMT) and intensive chemotherapy (ICC) in adult AML patients. Imagine these treatments as two distinct paths through the desert of cancer treatment, each with its own advantages and challenges.

The researchers compared the outcomes of these two approaches, finding no significant difference in disease-free survival or overall survival between autologous BMT and ICC. They also discovered that a second course of chemotherapy proved less myelotoxic than autologous BMT. This research highlights the need for individualized treatment plans, considering the unique needs of each patient.

A Personalized Journey: Tailoring Treatment to Individual Needs

This study emphasizes the importance of individualized treatment for AML patients. It demonstrates that there is no single 'best' treatment approach, and the choice of therapy should be tailored to the patient's specific circumstances and preferences. This research encourages a personalized approach, allowing patients to navigate the desert of cancer treatment on a path that best suits their needs.

Navigating the Desert: Seeking Effective and Personalized Care

This research emphasizes the importance of comprehensive care for AML patients. It highlights the need for careful consideration of treatment options, taking into account the individual patient's needs and preferences. This research encourages continued exploration and innovation in AML treatment, seeking to improve outcomes and offer personalized care for those navigating this challenging desert.

Dr. Camel's Conclusion

This study reminds us that the desert of cancer treatment is vast and complex. It's crucial to find the right path for each patient, considering their individual needs and preferences. The researchers' findings encourage a personalized approach, seeking to optimize outcomes and provide hope for those facing this challenging journey.

Date :
  1. Date Completed 1997-11-12
  2. Date Revised 2021-02-16
Further Info :

Pubmed ID

9376578

DOI: Digital Object Identifier

S0006-4971(20)57927-5

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.